No abstract

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by Big Pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that large pharmaceutical firms are increasingly becoming 'network integrators' rather than the prime locus of drug discovery.

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by Big Pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that large pharmaceutical firms are increasingly becoming 'networks integrators' rather than the prime locus of drug discovery.Keywords: Pharmaceuticals, bibliometrics, outsourcing, Europe, globalisation, research network, innovation, collaboration Highlights  We analyse the publications by R&D laboratories of the top 15 pharmaceutical firms.  We observe a slow decline in their total number of publications and field share.  A more pronounced decline in publications by R&D laboratories located in Europe.  There is more external collaboration and research in non-traditional disciplines.  The results suggest that Big Pharma firms are increasingly network integrators.

New method created to easily and safely detect prostate cancer pg 1712 Agreement signed for co-promotion and marketing of liver-based DMPK services pg 1713 LC-MS used for detection of caffeine in fingerprints pg 1713 News & Analysis Highlighting the latest news and research in bioanalysis Collaboration announced for development of biologics analysis Agilent Technologies to collaborate with two academic institutions to further biologics research Agilent Technologies (CA, USA), the University of Rouen (France) and the Bioprocessing Technology Institute (BTI) at the Agency for Science, Technology and Research (Singapore) are to collaborate in developing analytical tests for biologics -molecules such as antibodies that are used in combination with vaccines. Biologics are a particular bioanalytical challenge due to their size and heterogenous structure.

No abstract